Business, energy, technology, markets and global industry news from Business News Today

CERVINO

PharmaDeviceNews CERVINO
AbbVie is positioning etentamig as a monthly BCMA-directed bispecific treatment for heavily pretreated multiple myeloma patients. Representative image.
Pharma & Biotech

AbbVie’s etentamig cuts myeloma progression risk 60% as monthly bispecific strategy nears its real test

AbbVie will present full Phase 3 CERVINO data for etentamig after the BCMA bispecific produced a 74% response rate and reduced progression or death risk by 60% in heavily pretreated multiple myeloma.

Read More
AbbVie’s etentamig delivered strong Phase 3 efficacy in relapsed multiple myeloma while its monthly dosing strategy could broaden access to BCMA-directed bispecific therapy. Representative image.
Features & Analysis

AbbVie’s second-generation BCMA bispecific succeeded in Phase 3. What makes CERVINO commercially important?

AbbVie’s etentamig delivered a 74% response rate and reduced the risk of progression or death by 60% in the Phase 3 CERVINO trial. Its real competitive proposition, however, may be operational: monthly dosing after a single step-up dose could help move BCMA-directed T-cell therapy beyond specialist centres.

Read More